Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Prostate cancer vaccines receive a boost in funding

The development of two innovative new vaccines that are hoped to offer an alternative to castration therapy for men with recurring prostate cancer, is due for an $8 million boost in funding.

16 Jan 2014

Transgenomic, Horizon Discovery collaborate to develop improved genetic diagnostic tests with state of art controls

Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, and Horizon Discovery Ltd. (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced they have entered into a collaboration agreement to develop improved genetic diagnostic tests incorporating state of the art controls.

16 Jan 2014

Cognigram can detect early signs of MCI and Alzheimer’s disease

For patients over the age of 50, a routine physical exam at the doctor’s office typically covers a wide spectrum of medical biomarkers with one glaring exception, cognitive health. Unless there have been unusual mental changes or challenges in their daily life, tests of a patient’s attention, memory or brain processing speed is usually not part of a check-up.

15 Jan 2014

Illumina signs multi-year licensing agreement with Quest Diagnostics

Illumina, Inc. today announced it has entered into a multi-year licensing agreement with Quest Diagnostics, the world's leading provider of diagnostic information services, related to the use of Illumina's next-generation sequencing technology for clinical laboratory testing.

From Illumina, Inc. 9 Jan 2014

MicroRNA biomarker shows promise in predicting treatment response of ovarian cancer

Researchers at Case Western Reserve University have identified a microRNA biomarker that shows promise in predicting treatment response in the most common form of ovarian cancer - a breakthrough that has the potential to improve outcomes for patients with the disease.

9 Jan 2014

OASIS receives research award from MJFF to develop saliva-based, rapid test for Parkinson's detection, diagnosis

Oasis Diagnostics Corporation is the recipient of a research award from The Michael J. Fox Foundation for Parkinson's Research to validate OASIS' development of a non-invasive, saliva-based, rapid test for Parkinson's disease detection and diagnosis.

8 Jan 2014

NeoGenomics launches new test for detection of mutations in CALR gene

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched a new test for the detection of mutations in the calreticulin (CALR) gene. The CALR gene is a novel biomarker that was reported to be specific for myeloproliferative neoplasms (MPN) for the first time at the annual meeting of the American Society of Hematology last month.

8 Jan 2014

Study links racism-related factors and biological aging among African American men

A new study reveals that racism may impact aging at the cellular level. Researchers found signs of accelerated aging in African American men, ages reporting high levels of racial discrimination and who had internalized anti-Black attitudes.

8 Jan 2014

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.

8 Jan 2014

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Horizon Discovery and AstraZeneca have entered into a research, collaboration and license agreement to explore a range of oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets. This deal is the second collaboration between AstraZeneca and Horizon, and follows the announcement in April 2013 of an oncology discovery program to explore Horizon's first-in-class kinase target program, HD-001.

7 Jan 2014

Adenosine deaminase has potential to improve prognosis, diagnosis and treatment of ESCC

Esophageal Squamous Cell Carcinoma (ESCC), the major histological form of esophageal cancer, is the leading cause of cancer death worldwide. Scientists from the National University of Singapore (NUS) have discovered a biomarker, called adenosine deaminase acting on RNA-1 (ADAR1), which has the potential to improve the diagnosis, prognosis and treatment of this disease.

6 Jan 2014

Editing of protein-making sequences promotes development of ESCC, find NUS researchers

Esophageal Squamous Cell Carcinoma, the major histological form of esophageal cancer, is the leading cause of cancer death worldwide. Scientists from the National University of Singapore have discovered a biomarker, called adenosine deaminase acting on RNA-1, which has the potential to improve the diagnosis, prognosis and treatment of this disease.

6 Jan 2014

Metabolon raises $15 million in Series E financing

Metabolon, Inc., a world leader in metabolomics-based diagnostic tests and research services, announced today that it has raised $15 million in a Series E financing through the issuance of preferred stock.

3 Jan 2014

Researchers find inhibition of basic cellular process that contributes to schizophrenia

Surprisingly little is known about schizophrenia. It was only recognized as a medical condition in the past few decades, and its exact causes remain unclear. Since there is no objective test for schizophrenia, its diagnosis is based on an assortment of reported symptoms.

30 Dec 2013

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.

30 Dec 2013

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

The I-SPY 2 TRIAL, a randomized phase II clinical trial for breast cancer launched through a unique partnership with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium and sponsored by QuantumLeap Healthcare Collaborative has graduated the first two drugs from its innovative, multidrug standing platform trial.

27 Dec 2013

Oral ingestion of inosine compound raises urate levels, shows Parkinson's study

New findings published in JAMA Neurology from research into a potentially protective therapy for Parkinson's disease (PD) show that with medical supervision, urate levels may safely be raised while mitigating risk of complications such as gout.

27 Dec 2013

THRIL could be novel biomarker for immune activation, potential target for inflammatory diseases

Sanford-Burnham Medical Research Institute scientists have discovered a new molecule that forms when certain white blood cells-macrophages-are stimulated in response to pathogens.

27 Dec 2013

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.

23 Dec 2013

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the Type II variation to amend the Erbitux(cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC).

23 Dec 2013

Biomarker News and Research

Further Reading

Prostate cancer vaccines receive a boost in funding

Transgenomic, Horizon Discovery collaborate to develop improved genetic diagnostic tests with state of art controls

Cognigram can detect early signs of MCI and Alzheimer’s disease

Illumina signs multi-year licensing agreement with Quest Diagnostics

MicroRNA biomarker shows promise in predicting treatment response of ovarian cancer

OASIS receives research award from MJFF to develop saliva-based, rapid test for Parkinson's detection, diagnosis

NeoGenomics launches new test for detection of mutations in CALR gene

Study links racism-related factors and biological aging among African American men

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Adenosine deaminase has potential to improve prognosis, diagnosis and treatment of ESCC

Editing of protein-making sequences promotes development of ESCC, find NUS researchers

Metabolon raises $15 million in Series E financing

Researchers find inhibition of basic cellular process that contributes to schizophrenia

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

Oral ingestion of inosine compound raises urate levels, shows Parkinson's study

THRIL could be novel biomarker for immune activation, potential target for inflammatory diseases

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Industry Focus eBook - Protein Analysis (3rd edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo